HY035
/ Juventas Cell Therapy
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 26, 2026
A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=13 | Enrolling by invitation | Sponsor: Institute of Hematology & Blood Diseases Hospital, China
New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • CD7
1 to 1
Of
1
Go to page
1